Genmab — Maj 2020

[Sukkeralf]

Okay looks good - and data will be further updated at the ASCO meeting

[E_L]

no ≥Gr 3 CRS and no DLTs ; i guess that is the most important for now?

[E_L]

"Treatment is ongoing in 13 pts " from 41 does not seem much? or should i not read anyting into that?

[E_L]

then again, very ill patients with 3 to 5 prior lines of treatment.

[peter12]

Its dose escalation, so I guess not all are evaluated ? 44% CR sounds impressing

[gentogen]

For a dose escalation study this is crazy good

[gentogen]

the overall response rate (ORR) after induction treatment with DPd was 100%. ORR on day 100 post ASCT was 100%, 65% achieved ≥CR, and 81% achieved ≥VGPR. There was no treatment related mortality on day 100.

[transalp]

Go morgen.. der er stadig meget godt i vente..

[bibob]

God morgen. :-). Ja, og solen skinner

[Sukkeralf]

Teclistamab (JNJ-64007957)

[Sukkeralf]

https://meetinglibrary.asco.org/record/186864/abstract

[JKY_VH]

God morgen;-)

[Helge_LarsenPI-redaktør]

God morgen.

[GeorgeBest]

Amivantamab https://meetinglibrary.asco.org/record/184802/abstract

[Helge_LarsenPI-redaktør]

Tusinde tak GMAB, E L, Sukker og Gentogen.

[Helge_LarsenPI-redaktør]

Og GB.

[kkjoel]

Ritzau: "Biotekselskabet Genmab har fået løftet kursmålet til 1920 kr. fra 1750 kr. af finanshuset Bernst
ein.Anbefalingen er fortsat outperform, viser data fra Bloomberg News."

[kkjoel]

Og tusinde tak for acso links

[bibob]

How does Genmab's ( CPH:GMAB) P/E compare to its industry, after its big share price gain. ? https://finance.yahoo.com/news/does-genmabs-cph-gmab-p-044804707.html

[Darvin]

Kendt, men skal måske
også nævnes Tisotumab https://meetinglibrary.asco.org/record/191701/abstract